BioSpace News Archive

Tenaya Therapeutics, Inc. today announced the pricing of its underwritten offering of 8,888,890 shares of its common stock at an offering price of $4.50 per share.

Leiden, The Netherlands, February 8, 2024: Pharming Group N.V. announces that Pharming’s management will participate in the following investor conferences in the month of February.

Rockwell Medical, Inc. announced that it will release its financial and operational results for the fourth quarter and full-year ended December 31, 2023 on Thursday, March 21, 2024.

Foghorn ® Therapeutics Inc. today announced that Lilly has selected FHD-909, a first-in-class oral BRM selective inhibitor, for clinical development. Lilly plans to file an IND for FHD-909 in Q2 2024.

Zimmer Biomet Announces Fourth Quarter and Full-Year 2023 Financial Results.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Ionis and AstraZeneca’s eplontersen, an investigational therapy for the treatment of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) in adults.

Beacon Therapeutics Holdings Limited announced the presentation of 12-month interim safety and efficacy results for the Phase 2 SKYLINE trial in patients with X-linked retinitis pigmentosa (XLRP) at the 47th Annual Macula Society Meeting in Palm Springs, California.

Domain Therapeutics today announces the appointment of Sean A. MacDonald as its Chief Business Officer (CBO) and member of the executive management team.

Theralase Technologies Inc. is pleased to announce that Dr. Michael Jewett has joined Theralase in the role of an independent consultant, to assist the Company in the completion of enrollment of patients in the Phase II Bacillus Calmette-Guérin (“BCG”)-Unresponsive Non Muscle Invasive Bladder Cancer (“NMIBC”) Carcinoma In-Situ (“CIS”) clinical study (“Study II”).

AmplifyBio CEO J. Kelly Ganjei Discusses Solutions for Reducing Costs and Risk in Advanced Therapy Manufacturing During Fireside Chat at Advanced Therapies Week.